CMS Open Payments · Program Year 2024
Taiho Oncology, Inc.
Taiho Oncology, Inc. reported $17,611,301.25 across General Payments, Research, and Ownership to 5,970 physicians and teaching hospitals across 6,767 transactions.
- $17.6M
- All-tracks total
- 6,767
- Transactions
- 5,970
- Recipients
- −$811.9K
- General Payments vs PY2023
Taiho Oncology, Inc. reported $17,611,301.25 across all CMS Open Payments tracks (General + Research + Ownership) to 5,970 physicians and teaching hospitals in Program Year 2024 - ranking #104 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $844,416.49, averaging $2.9K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer taiho-oncology-inc Taiho Oncology, Inc.
$17.6M · #104/1,925 · 0.1% industry · PY2024
- TOT $17.6M
- RANK #104
- SHARE 0.1%
- TXN 6,767
- RCP 5,970
- CAT 7
- GEN $844.4K
- ΔGEN −$811.9K
- TOP1 10.8%
- PY 2024
Volume peers
Nearest volume peer: Becton, Dickinson and Company ($17.8M)
Taiho Oncology, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Taiho Oncology, Inc.'s CMS-reported General Payments decreased by $811.9K (−49.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TAIHO ONCOLOGY, INC.PY2023: TAIHO ONCOLOGY, INC.PY2024: TAIHO ONCOLOGY, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,656,279.19
- PY2024
- $844,416.49
What the Data Shows for Taiho Oncology, Inc.
$17,611,301.25: that is what Taiho Oncology, Inc. reported in payments to 5,970 physicians and teaching hospitals during Program Year 2024, spread across 6,767 transactions ($2.6K per transaction, $2.9K per recipient). The company sits at rank #104 of 1,925, representing 0.1% of all industry payments reported nationwide for the year.
The 7-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $340.3K, accounting for 40.3% of this company's General Payments and 97 transactions.
General Payment Breakdown by Type
Taiho Oncology, Inc. made 7 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $340.3K, 40.3% of General Payments.
Taiho Oncology, Inc. reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (40.3%), Consulting Fee (25.3%), and Food and Beverage (14.7%). The remaining 4 categories make up 19.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Taiho Oncology, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $340.3K | 97 | 40.3% |
| Consulting Fee | $213.5K | 106 | 25.3% |
| Food and Beverage | $124.3K | 5,407 | 14.7% |
| Space Rental or Facility Fees | $94.0K | 29 | 11.1% |
| Travel and Lodging | $57.4K | 288 | 6.8% |
| Education | $10.4K | 9 | 1.2% |
| Compensation for Faculty or Speaker (Medical Education) | $4.5K | 34 | 0.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $197,775.42 (23.4%) of $844,416.49 in this company's General Payments records across 3,227 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Taiho Oncology, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Michael Morse
$91,456.88 across 84 reported transactions
- 2
Bart Scott
$31,667.39 across 20 reported transactions
- 3
Ben George
$29,469.83 across 19 reported transactions
- 4
Mayo Clinic Hospital
$22,595.00 across 5 reported transactions
- 5
Putao Cen
$22,586.32 across 22 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Taiho Oncology, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Taiho Oncology, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Taiho Oncology, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Ultragenyx Pharmaceutical Inc.
CSL Plasma Inc.
Sarepta Therapeutics, Inc.
Spinecraft, LLC
Align Technology, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.